Biotech Values

[DewDiligence]

>I'm not so sure KOSP should be happy. Merck may be very happy with their internal niacin program and perhaps sees no need for an analog if their flushing inhibitor is doing its job well.<

Wouldn’t KOSP prefer to have only one competing product to worry about instead of two?

I’m not sure I draw the same inference as you do that MRK’s dropping the ARNA candidate is bullish for MRK’s internal niacin program. It could mean that, but it could also mean that ARNA’s drug simply didn’t work.